

GIDR WORKING PAPER SERIES

No. 188: November 2008

**Role of critical infrastructure and
incentives in the commercialisation of
Biotechnology in India: An analysis**

S. Visalakshi



Working Paper No. 188

**Role of critical infrastructure and incentives in the
commercialisation of Biotechnology in India: An analysis**

S. Visalakshi

November 2008

**Gujarat Institute of Development Research
Gota, Ahmedabad 380 060**

Abstracts of all GIDR Working Papers are available at the Institute's website.
Working Paper No 121 onwards can be downloaded from the site

All rights reserved. This publication may be used with proper citation and due acknowledgement to the author(s) and the Gujarat Institute of Development Research, Ahmedabad.

© Gujarat Institute of Development Research

First Published	November 2008
ISBN	81-89023-46-2
Price	Rs. 40.00

Abstract

Commercialization is a process by which the new knowledge is converted to products and services of commercial value. The model for commercialization of biotechnology is not a linear one. Due to emerging status of knowledge and involvement of biological systems legal and ethical challenges also arise and make the commercialization process longer, costlier and risky. Despite these entry barriers, we find many countries have appreciated the potential of biotechnology to produce useful and safer products and services in many areas of human activity and have invested and reaped fruits in terms of successful products in the market. We find from these accounts the results vary with the level of maturity of the industry and priority assigned by the nations and investments made in skills and generation of new knowledge. Among the developing countries, India is one of the early investors in biotechnology. Efforts were started as public initiatives. Skill generation, infrastructure development along with knowledge generation was taken up by the Department of Biotechnology. Multi-pronged efforts established visible capabilities in the public research system. Despite these efforts for past one and half decades very little has happened at the commercialization level. This gap in realization of Indian research efforts as commercial successes has been a puzzle. In this paper, the author attempts to investigate the reasons behind slow commercialization. The approach is based on the hypothesis that to achieve successful commercialization in knowledge intensive field with high rates of turn over like biotechnology, the company should have (i) high levels of capabilities in R&D and strong network, to supplement and complement skills and facilities and (ii) an environment which is highly facilitating (high levels of preparedness of the technology delivery system) through favourable policies for regulation, accessing fiscal resources in terms of finances, infrastructure and skills, fiscal incentives, enhancing awareness of the public etc.

Keywords : Commercialisation, Incentives, Infrastructure

JEL Classification : O32, Q16

Acknowledgements

The study was sponsored by Technology Information Forecasting and Assessment Council (TIFAC). I express my sincere thanks to the GIDR Ahmedabad for publishing this as a Working Paper, which was finalised during my visiting fellowship at GIDR during November 2007 - April 2008. I thank Prof. Biswajit Dhar, Indian Institute of Foreign Trade (IIFT), for his valuable comments and suggestions on the earlier draft. Executives of the selected companies are thanked for participating in the survey and for their inputs. Ms. Tara Verma is thanked for typing the manuscript. I am grateful to Prof. R.K. Kochhar the then Director, NISTADS for his encouragement. The usual disclaimers apply

Contents

	Page No
Abstract	i
Acknowledgements	i
Contents	ii
List of Charts/ Tables	ii
1. Introduction	1
2. Commercialisation in the Innovation Process	2
3. Theoretical Framework and Methodology	3
4. Incentives	4
5. Indian efforts in Biotechnology	6
6. Sample selection and description	7
7. Problems faced by companies during commercialisation	8
8. Unique problems	10
8.1. Fiscal Incentives	11
8.2. Infrastructural	11
8.3. Policy related	12
8.4. Skill related	12
9. Conclusions and Discussion	13
References	15

List of Charts / Tables

Chart 1:	Typical Commercialisation process of biotechnology	2
Chart 2:	Schematic representation of commercialisation of biotechnology	3
Table 1:	Product Segments	8
Table 2:	Constraints identified as affecting commercialisation of biotechnology	9

Role of critical infrastructure and incentives in the commercialisation of Biotechnology in India: An analysis

S. Visalakshi[§]

1. Introduction

Commercialization is a process by which the new knowledge is converted to products and services of commercial value. The model for commercialization of biotechnology is not a linear assembly like model. It requires constant touch with research for the paradigm is not ‘expansion of scale’ but ‘expansion of scope’. Commercialization, in addition to this continued connection with research or knowledge generating units, requires patronage of policy makers to facilitate the process be it protection or regulation and also an environment in which required skills materials, channels of distribution and awareness of ultimate consumer. Due to emerging status of knowledge and involvement of biological systems legal and ethical challenges also arise and make the commercialization process longer, costlier and risky. Hence “patronage of policy makers” is particularly significant in the case of biotechnology though some of the above conditions are valid for any frontier technology.

Despite these entry barriers, we find many countries have appreciated the potential of Biotechnology to produce useful and safer products and services in many areas of human activity and have invested and reaped fruits in terms of successful products in the market. We find from these accounts the results vary with the level of maturity of the industry and priority assigned by the nations and investments made in skills and generation of new knowledge. Among the developing countries, India is one of the early investors in biotechnology. Efforts were started as public initiatives. Skill generation, infrastructure development along with knowledge generation was taken up by the Department of Biotechnology. Multi-pronged efforts established visible capabilities in the public research system. Despite these efforts for one and half decades very little has happened at the commercialization level. This gap in realization of Indian research efforts as commercial successes has been a puzzle. In this paper, the author attempts to investigate the reasons behind slow commercialization.


[§] S. Visalakshi is Scientist at the National Institute of Science Technology and Development Studies, New Delhi, Email: visalakshi@nistads.res.in, visha_3@yahoo.com

2. Commercialisation in the innovation process

In the innovation process, commercialisation is a relatively costly and difficult phase. It is the process of taking new knowledge, process or product beyond R&D phase and actually introducing it into production or in the market place. The location of this process is in the business sector and the R&D results may be self generated or outsourced. There is a widely quoted 'rule of thumb' that for every dollar spent on research 10 dollars are spent in Development and 100 dollars for commercialisation. The ratio thus is R:D:C is 1:10:100. This magnitude becomes one of the major inhibiting factors to commercialisation in developing countries. Though this ratio varies among industries, it is largely true for large process-oriented projects where pilot plants and lot of regulatory compliances are required.


Though commercialisation occurs through the companies, many a times the technology to be commercialised is developed outside the company. The major sources are public research system or other companies within or outside the geographical boundaries through different instruments of technology transfer. The nature of impediments vary depending on the nature, characteristics and maturity of the technology or know how transferred to the company. Thus the typical commercialisation process can be depicted as in Chart 1.

Chart 1: Typical Commercialisation process of biotechnology



The efficiency with which the know-how transferred to a company goes through the intervening phases to commercialise different products /services depends primarily on two factors. First: the inherent capacity of the firm to absorb new knowledge and proceed with further steps. Second: factors external to the company like policies, market, network, and supportive infrastructure & financial mechanisms. Thus it seems to be a combination of strength/competence (technical, managerial and marketing) of the company, which is commercialising the technology and environment congenial for this which leads to successful commercialisation. Thus the whole process can be schematically depicted as in Chart 2 below:

Chart 2: Schematic representation of commercialisation of biotechnology



Thus the commercialisation process to succeed requires: (a) sound research base; (b) technologically competent companies; and (c) congenial and encouraging environment. The status of knowledge in the field, organization of knowledge generation and transfer processes and implementational strategies adopted by different countries are important factors which influence and lead to different results. In this paper we restrict our study to the status of commercialisation of biotechnology in India.

3. Theoretical Framework and Methodology

According to Batherham (2000) companies which want to succeed in new economy need to invest in new skills and technology and align themselves with research institutions that perform basic research. According to an Australian report (Anonymous 2002), success factors in the commercialization path are listed as R&D products and services, IP protection, market analysis, regulatory issues, alliances and collaboration and availability of capital. This partially compares well with our identified factors. Furman et al (2002) observe common innovation infrastructure include (1) cumulative technological sophistication, (2) human capital resources available for R&D activity and (3) resource commitments and policy choices such as investment in education & training, IP protection, openness to international trade and R&D tax policies. Of Furman et al's list we consider R&D tax policies as part of incentives.

As mentioned earlier, of the two major factors affecting the process and pace of commercialization we look at the factors external to the company i.e critical infrastructure and incentives. The other factor relating to the companies' capability has been dealt with in the earlier studies (Visalakshi & Sandhya 2000, Ramani & Visalakshi 2001, and Visalakshi 2006). The infrastructure critical to BT commercialization, according to us, include skill, funds and supportive institutions and industry, market and required policies in place.

While listing out the various factors we realize some of the factors serve as part of infrastructure as well as new rules/amendments serve as incentives. For example as strong IP law operative in a country could become part of infrastructure while an amendment which favours inclusion of living modified organism could be an incentive for biotech research and commercialization.

4. Incentives

Incentives are measures that are put in place to induce people and organizations to generate positive outcomes. In the case of science and technology, the different types of incentives can be classified in terms of: (a) Fundamental incentives; (b) Institutional and infrastructural incentives; (c) Financial & Fiscal incentives; (d) Budgetary incentives; (e) Legal and regulatory incentives; (f) Government procurement incentives; (g) Honorific incentives; and (h) Knowledge-base incentives.

- (a) The fundamental incentives are those which may stated as initial conditions for socio-economic development, such as those provided by a market economy which includes free competition, private property, openness to the global economy, efficient bureaucracy and a stable democracy.
- (b) Institutional and infrastructural incentives could be made more efficient, particularly those for technological innovation (such as science parks), transfer, extension, diffusion, popularization, information, networking (including professional associations) and international cooperation. While institutions and infrastructures for R & D need to be modernized, strengthened and better linked to industry, infrastructures for information and communication technologies are particularly important for any developing countries since these technologies can substantially improve productivity and efficiency in all sectors of the economy and support technology transfer and networking. Hence the need to put into place incentives for their application and diffusion.
- (c) The financing of technological change is of paramount importance for developing countries, which lack a full-fledged financial system and which attract little foreign direct investment and commercial credit. The strengthening, privatization and diversification of the financial system should be a high priority in order to increase the availability of venture capital and of small credit to farmers and the informal sector. Financial incentives in general and incentives for foreign direct investment in particular need to be reinforced in view of the globalisation of the economy, by removing or reducing constraints in respect of percentage of local equity, local inputs and repatriation of dividends. A more positive approach to multinational corporations is needed if they are to contribute to endogenous technological

capacity building. The use of fiscal incentives, such as tax exemptions, rebates, reliefs, holidays, and accelerated depreciations, can be used to promote R & D, linkages with industry, application of technology, training, the return of national expatriates, use of foreign consultants, strategic technology import, etc. Many countries have established or are in the process of setting up Export Processing Zones, essentially with tax incentives and facilities for the transfer of technologies, such as more freedom to hire expatriate experts.

- (d) Budgetary incentives, except scholarships, are more and more regulated by the new WTO agreements, particularly investment allowances, modernization grants, industrial subsidies and export compensations. This should be to the advantage of countries which cannot compete with the industrialized countries in subsidizing industry.
- (e) Legal and regulatory incentives are essential to protect intellectual properties and technologies, to enforce minimum technological standards, to facilitate the hiring of essential foreign experts (residence and work permits, tax holidays) and to discriminate technology imports. In Africa this type of incentives has also been used to enhance the status of researchers. Legal and regularity incentives need to be reviewed from time to time to adjust to changing circumstances. For instance, technology flows are more and more regulated by the market than by bureaucratic regulations although some regulations are needed.
- (f) Government procurement can provide important incentives to local industries to upgrade their technological capacity. India is currently not bound by the WTO disciplines on government procurement policies, and can therefore use such policies for the benefit of indigenous enterprises. Honorific incentives, such as prizes and awards, are public recognition of excellence and have proved to be particularly cost-effective in promoting innovation and technological improvement.
- (g) Incentives to strengthen the knowledge base, such as basic education, encouragement to take science disciplines, technical training, apprenticeship, sabbatical leaves, study tours, participation in international seminars, etc. are extremely important for any socio-economic development. Incentives are the tools which can be used to manage technological change and are vital for socio-economic development.
- (h) Incentives can be non-fiscal which may include infrastructure development for industry use like incubators and technology parks, or expanding access to skills through academia-industry interaction, supportive policies for regulation,

intellectual property protection, licensing and product approvals, establishment of testing facilities and standards and creation of awareness of public about Biotechnology.

5. Indian efforts in Biotechnology

Among the developing countries, India is one of the early investors in biotechnology. Efforts were started as public initiatives. Skill generation, infrastructure development along with knowledge generation was taken up by the Department of Biotechnology (DBT). Multi-pronged efforts established visible capabilities in the public research system. Despite these efforts for one and half decades very little has happened at the commercialization level. With its existing strengths of research capabilities and infrastructure there is a growing expectation from Indian industry to commercialize biotechnology products. There are around 200 firms working in different sectors like healthcare, agriculture etc. Though there are about dozen products marketed in the country, only a few products are commercialized based entirely on indigenous efforts. This gap in realization of Indian research efforts as commercial successes has been a puzzle and to fill this gap DBT has been making various efforts in form of policies, schemes and support for the past decade with very little success. Outputs of Indian biotech research have been predominantly publications in journals and in conferences. Though around 40 technologies have been claimed to be transferred with the efforts of DBT hardly any product has come out of these transfers. Human resource generation in India was initiated and continues to be under DBT's functions. Though the number of institutions training has increased, there is a severe shortage of manpower perceived by the BT industry in terms of both quality as well as quantity.

Even though India has invested in BT for about two decades (amounting to over 10 billion rupees) and has created over 300 research groups, more than 40 institutions training around 1000 post graduates and post doctoral fellows, the outcome has been only few products. Currently around 200 companies are involved in BT related activities, most of which are small in size. Of these, around 50 companies are involved in modern biotechnology (which includes recombinant DNA and cell fusion, like hybridoma technology techniques). All the above mentioned portend to some grave problems that are encountered in commercializing BT in India. In this article, the author looks at the role of critical infrastructure and incentives in the context of commercialization of BT and Indian experience on this.

In order to find out the factors which may not hit the casual observer or could be inferred from the large data available at different sources on Indian Biotechnology, that come in the way of commercializing biotechnologies in India a detailed and in- depth study was necessary. This paper presents the results of the study undertaken during 2003-2004.

Studies by Visalakshi *et al* (1993) which analyses 4 cases and Ghosh (1996) (analysed 17 cases) throw light on the effort of commercialisation in BT in the late 1980's and 1990's. Obstacles to commercial success identified by these studies are the following:

- Institutions involved in R&D did not go beyond basic and applied research and had no funds or skills to do development, up-scaling etc.
- Joint development of products by research institutions and industry were very rare or non-existent, for reasons of confidentiality etc.
- Reward system which was in place does not encourage post R&D phase activities by the investigating or technology managers to get involved.
- Industry is lacked the skills to absorb the technology developed by R&D institutions and to set up production facilities.
- Lack of sufficiently strong patent protection discourages investment by industry in serious basic research.

While some of the problems identified by the above studies have been addressed, others continue to play a part in influencing commercialization of R&D results. The changing patent laws, evolving regulatory framework, and coming into being of new business efforts in the post- genomic era etc, have created a need to have a look into the status of Indian biotechnology and its commercialisation and draw sufficient insights for further action.

6. Sample selection and description

The sample was derived from various lists like the one by Biotechnology Consortium of India Ltd (BCIL) and added to the list companies from other sources. We had a list of about 350 companies involved in BT and BT related activities in the country. Of these 52 companies did not have valid contact information. Some of them we learnt later as not existing any more and some are still in the initial stage of formation.

Of the remaining companies, about 222 in number, the project team could visit 162 companies located in Ahmedabad, Aurangabad, Bangalore, Chennai, Delhi, Hyderabad, Jalna, Mumbai, Pune, Surat and Vadodhara. We collected from secondary sources the required information for the remaining 60 companies.

The sample had a mix of small, medium and large companies. The ownership of the companies in the sample covered all types like public, private, MNCs and joint venture companies. The nature activity was from research alone to research, production and marketing. The nature of technology used varied from modern biotechnology, traditional biotechnology and marginal biotechnology. The areas of operation were spread from agriculture, health, industrial

biotechnology, instrumentation etc. The product segments in which the selected companies were active are as shown in Table 1.

Table 1: Product Segments

Product segments		
<i>1. Agriculture</i>	<i>2. Healthcare</i>	<i>3. Industrial BT</i>
(a) Aquafeed	(a) Biotherapeutics	a) Enzymes
(b) animalfeed	(b) Diagnostics	(a) Instruments
(c) biofertilizer	(c) drugs/therap.	(b) Res. Biology & reagents
(d) Biopesticide	(d) Probiotics	(c) CRO
(e) Seeds (Hybrid)	(e) Vaccines	(d) CLRO
(f) Seeds (Transgenic)		(e) Bioinformatics/ genomics
(g) Plant nutrients and others		

The information sought pertains to: (a) earlier efforts at commercialisation of BT; (b) problems faced; and (c) experience based opinion on incentives/ facilitators of commercialization

A questionnaire was devised with three sections. An elaborate section on the capabilities in terms of technologies transferred from various sources to the company and the types of problems faced in adapting and commercializing the same. The last section was on incentives they required to overcome problems/impediments. The data collection was done by both mail and by personal interviews using semi-structured questionnaire.

7. Problems faced by companies during commercialisation

Based on the responses given by the companies visited and involved in biotechnology we have been able to find constraints to successful commercialisation of biotechnology in Indian context. We observed that they can be grouped under categories, viz. (a) policy; (b) fund/finance; (c) skill; (d) infrastructure; (e) linkage; (f) market/consumer; (g) external influence like activities by countries outside the India

List of factors which affect commercialisation of are of two types. One set of factors which were recognized as common to many companies irrespective of their size, type of products they deal with, nature of their activities, nature of technology used and level of biotechnology involved. The other set includes factors which are specific to companies based on products or size etc. As the techniques used is linked to the product many a times we did the analysis as per product groups. Examples are bio-pesticides and vaccines.

Table 2 gives the constraints identified by companies across the board under different categories.

Table 2: Constraints identified as affecting commercialisation of biotechnology

Category	Actual constraints
Funds	<ul style="list-style-type: none"> • VC funds by state are stringent & difficult to get • Private VC companies are risk averse • Current funding pattern is not meeting entrepreneurs' needs • VC's are insensitive to specific features of BT • Lack of awareness of banks about requirements of BT • Financial crunch stops collaborative projects as public R&D charges exorbitantly for facilities the services
Fiscal	<ul style="list-style-type: none"> • Tax holidays for BT are not there • Insensitive duty structure • Non existent sales tax concessions, exemptions etc
Skill	<ul style="list-style-type: none"> • Public R&D outcomes are not amenable to commercialisation • Academics lack entrepreneurial capability • Mismatch between manpower generated by public system and industry's needs • The manpower generated are more of technicians (good at repeating work) than being creative/ innovative
Policy	<ul style="list-style-type: none"> • Non clarity about status of new business propositions – CROs, CLRo's, diagnostics etc • Complicated & long licensing procedures • Non exclusive licensing discourages Technology transfer
External factors	<ul style="list-style-type: none"> • Dumping of cheap products by certain countries discourage new ventures
Market	<ul style="list-style-type: none"> • Prohibitive cost of creating and developing market in India and abroad
Infrastructure	<ul style="list-style-type: none"> • Lack of incubators • Lack of concessions for power usage • 3.Lack of consultancy support for establishing new ventures
Linkage	<ul style="list-style-type: none"> • Procedural problems discourage interaction with public research. Institutions • Lack of confidence, common language and transparency in interaction with academic partners • Lack of awareness of research institution about requirements of industry and product development
Organisational attitudes	<ul style="list-style-type: none"> • Lack of appreciation of applied research. work & efforts to transfer technology • Lack entrepreneurial capability among public institute scientists • No encouragement for industry public R&D interaction • Lack of rewards to scientists (patents in the name of organization and not inventor)

From the above table, one can make out that funds and skills are major problems. Lack of understanding specificities of BT and its products appear to be coming in the way of devising facilitating policies which would encourage commercialisation of biotechnology.

When the list of constraints was analysed to see any relationship with size of the company, we find finance related problems are more for small companies and policy related problems are faced mainly by large companies.

Companies with well established R&D facilities in their own companies have found accessing skill from public research system as a problem, while companies with less developed or no R&D of its own find lack of structures facilitating linkages with public R&D as a major obstacle.

It is observed that companies involved in marginal biotechnology had no problems of regulatory policies. Some of the companies involved in Traditional Biotechnology faced policy related problems like duty structure, definition/categorization of products etc. Policies related to regulation and IP protection were felt as not clear and arbitrary which affected their activities and strategies for the companies engaged in modern biotechnology (MBT). These companies also felt the problems related to consumer awareness and market development.

Problem faced by companies attempting commercialisation of products under different segments may be summarise the nature of problems vary with different product segments. Diagnostics have predominantly policy and policy derived market problems. Similar is the case with the production of new seeds including transgenics and biopharmaceuticals.

Finding finance and developing market seems a major problem of support / service companies like instruments and reagent companies. Probiotics, micronutrients, Tissue culture, biopesticides and biofertilizers companies have in common problem related to market in terms of awareness competition and spurious products leading loss of confidence. They all also have infrastructure problems in terms of QC, standards, testing facilities etc. Vaccines, enzymes, biopharmaceutical companies find a problem in low level academia industry interaction.

8. Unique problems

Enzymes companies are unique in that the non stringent environmental regulation is a road block in creation of markets. Bio informatics companies want more stringent IPR laws in place and implemented.

Biopharma companies are constrained greatly by lack of USFDA compliant infrastructure for clinical and pre-clinical trials. Instruments companies find absence of recognition of their connection to BT and special treatment reason coming in their way of success. Biopesticide

and biofertilizer companies feel pressure of chemical companies lobby working against their good. They also find the registration process is lengthy and cumbersome. Diagnostics companies find lack of sera panel availability, rules for public procurement requiring companies to be in market for 2 years coming in the way.

Thus there are many factors identified which are creating problems for commercialisation of BT. The problems common to all are few and related to procedures and weak infrastructure, while those specific to various type of products are many. One could see some dependence of problems to size viz. small companies have more finance related problem than large ones, which have can muster, enough resources.

Based on the opinions of companies, incentives which could facilitate the process of commercialisation has been drawn. We found they could be grouped under the heads - fiscal, infrastructural, policy/ procedures and skill.

List of incentives felt as required by the companies attempting commercialization basically fell into 4 categories, viz: (i) fiscal, (ii) infrastructure related, (iii) policy related, and (iv) skill related.

8.1. Fiscal Incentives

1. Incentives like tax benefits for export (as IT companies get) and reinstatement benefit which has been withdrawn for manufacturing companies who export
2. Tax benefits/ holidays
3. Favourable exchange rate for export
4. 50% subsidy for capital expenditure in BT
5. Duty free import of machinery
6. Sales tax to be reduced in case of over competition (reducing greatly profit margin)

8.2. Infrastructural

1. Encouragement to collaborate with research institutes
2. BT instruments, reagent manufacturers/suppliers need special treatment
3. Testing, standards institutions to be created for recombinant therapeutics, regulatory data generation for transgenic, standard animal houses for preclinical, clinical facilities or at least identification and authorization of such facilities outside the country for compliance data generations

4. Increasing awareness of VCs and financial institutions about BT business
5. Establishment of quality standards and testing/ certifying facilities
6. Land allocation on priority basis and at concessional rates (China gives it free of cost)
7. Awareness creation (support) for BT products among consumers, beurocrats, policy makers and implementing agencies.

8.3. Policy related

1. Ban on import of BT products (diagnostics, vaccines drugs etc) when domestic capacity to produce exists
2. VCs to be equipped with technical people for approval of proposals in BT
3. VCs should have more freedom from CAG to take decisions in BT (despite high risk and long gestation)
4. Industrial R&D should be supported by public funds without strings of collaboration with public research organisations. which charge exorbitantly
5. Matching grant for people who want to put up incubators, or establish incubators for small and entrepreneunial ventures
6. Harmonized system of classification of BT products which form the basis of tax structures for excise, import etc.
7. Single window regulatory /licence clearance

8.4. Skill related

1. Facilities for field demonstration new agri BT products to be enhanced
2. Industry academic interaction to be encouraged
3. Skill generation through cooperation and consultation with industry
4. Consultancy/ guidance for starting new ventures in BT
5. Facilitation of technology scouting

From the above list, we can observe that they are corollary of the constraints faced. The incentives accordingly fall under fiscal, skill, infrastructure, awareness creation, easing procedure licensing, trade and regulation.

Similarly there are incentives related to size product made technology used etc .Smaller companies look for more grants loans, and infrastructural support while companies which are

big and established look for tax related incentives and lax regulatory but stringent IP laws.. Across size, companies feel a need an incentive in awareness creation for consumers, establishment of testing facilities and standards, clarity among bureaucrats policy makers about biotechnology.

9. Conclusions and Discussion

From the above analysis it comes out clearly that having a robust infrastructure and creation and existence of vibrant incentive structures can make a difference to outcomes of developing countries efforts to commercialize new knowledge. These become still more critical in knowledge intensive areas like biotechnology. In the case of developing countries, the companies in which commercialization occurs usually lacks capabilities at optimal level and hence depends on the technology delivery system (TDS) (Porter et al 1980) for its better performance. It is also observed that preparedness of TDS complements sub optimal capabilities in the companies (Visalakshi & Sandhya, 2000) in the case of Indian Biotechnology. Our study brought out in an indirect way that problems and insufficiencies in these two factors become an impediment to successful commercialization. The major problems relate to skills, and funds. The findings coincide with those of a study done in Australia (Anonymous 2002). It is more felt by smaller companies as they are at start up stage and have no assets to prove their credibility or no revenue coming their way to plough back. This insufficiency also affects hiring people with suitable skills. This to an extent is taken care of by linkages with local public sector research institutions or universities. Some of the small companies have been promoted by technical persons who have contacts with these institutions; and use facilities available with these institutions for their work till their infrastructure gets set up and established).

Large companies do not have much problem with funds, some problem with skills matching their requirement but policies are impediments by delaying the date of return on their investments.

Incentives as they exist are less attractive and awareness of these also is very low and in many cases these schemes are under-utilized. Because of an overall precautionary approach lots of strings are attached to these grants-in-aid, and soft loans types of funding of innovation in new areas. These conditions prohibit some of the companies to make use of them, for eg., to be eligible for the grants/loans the company needs to tie up with a public research institution which always does the projects on time over run. The other factor which discourages tie up with public and academic institutions is the exorbitant costs for services and facility usage. Policies relating to IPR, and regulation are still in the process of evolving.

Thus the whole situation has a great negative effect on the pace of commercialization. Public research system and companies in India has for historical reasons remained isolated from each other. Now there is a realization of mutual dependence due to new policies and global aspirations. Still there is certain level of hesitation from either side in working together in a collaborative mode.

From the above facts, figures and analysis of biotech companies in India, one is able to find some answers and reasons for slow commercialization of BT. It is expected that continuing efforts and investments for development of BT in India by the Government since last two decades, recent enthusiasm shown by the industry and more savvy and aware policy making bodies would change this into more robust infrastructure and facilitating incentives combining improved capabilities in the companies to lead to commercialization of larger member of products at a faster pace.

References

- Anonymous (2002), Commercialisation: paths Models and barriers in Report on Australian Biotechnology, p. 45-52.
- Batherham (2000), The Chance to Change, Report, November, p. 81.
- Furman J.L., Porter M.E. and Stern S. (2002), The determinants of national innovative capacity, *Research Policy*, 31, 899-933.
- Ghosh P.K. (1996), Indian Experience in Commercializing Institutionally developed Biotechnologies, *Journal of Scientific and Industrial Research*, 55 (November): 860-872
- Porter A.L., Rossini F. A., Carpenter S. R. and Roper A. T. (1980), Guide Book for Technology Assessment and impact analysis, New York, North Holland.
- Shyama, V. Ramani and S. Visalakshi (2001), Chicken or the Egg problem revisited: The role of Resource and Incentives in the Integration of Biotechnology, *International Journal of Biotechnology*, 2(4): 297-312.
- Visalakshi, S. (2002), Challenges before Pharmaceutical Industry in India and strategies to cope with them: an Analysis in International Conference on Health care and food: Challenges of intellectual property rights, biosafety and bioethics held at New Delhi, 1-5 Dec, 2002.
- Visalakshi, S. (2006), "Role of Critical Infrastructure and incentives in the Commercialisation of Biotechnology in India: An Analysis", paper presented at the 9th International Conference on Technology Policy and Innovation at Santorini (Greece) during 18-21st June, 2006.
- Visalakshi, S and N. N. Mehrotra Poonam Tandon (1993), Evaluation of Technology Transfer in India: A case study of healthcare related biotechnology, *International Journal of Technology Management*, Special Issue, pp. 129-141.
- Visalakshi, S & G.D. Sandhya (2000), R&D in Pharma Industry in Context of Biotech Commercialisation, *Economic and Political Weekly*, 35 (48): 4223-4233.

THE GIDR WORKING PAPER SERIES (No. 140 onwards)

- 140*. Uma Rani, "Economic Growth, Labour Markets and Gender in Japan", July 2003. Rs. 45.
- 141*. R. Parthasarathy and Jharna Pathak, "The Guiding Visible Hand of Participatory Approaches to Irrigation Management", August 2003. Rs. 30.
- 142*. Keshab Das, "Competition and Response in Small Firm Clusters: Two Cases from Western India", September 2003. Rs. 30.
143. B.L. Kumar, "Target Free Approach for Family Welfare in Gujarat: A Review of Policy and Its Implementation", October 2003. Rs. 40.
- 144*. Amita Shah, "Economic Rationale, Subsidy and Cost Sharing for Watershed Projects: Imperatives for Institutions and Market Development", March 2004. Rs. 35.
145. B.L. Kumar, "Tribal Education in Gujarat: An Evaluation of Educational Incentive Schemes", June 2004. Rs. 45.
- 146*. R. Parthasarathy, "Objects and Accomplishments of Participatory Irrigation Management Programme in India: An Open Pair of Scissors", July 2004. Rs. 40.
147. R. Parthasarathy, "Decentralisation Trajectories with Multiple Institutions: The Case of PIM Programme in India", August 2004. Rs. 30.
- 148*. Amita Shah, "Linking Conservation with Livelihood: Lessons from Management of Gir-Protected Area in Western India", September 2004. Rs. 40.
149. B.L. Kumar, "Primary Health Care in Gujarat: Evidence on Utilization, Mismatches and Wastage", October 2004. Rs. 40.
150. B.L. Kumar, "Schools and Schooling in Tribal Gujarat: The Quality Dimension", November 2004. Rs. 35.
- 151*. N. Lalitha, "A Review of the Pharmaceutical Industry of Canada", December 2004. Rs. 35.
152. Satyajee Nanda, "Micro Determinants of Human Fertility: Study of Selected Physiological and Behavioural Variables in SC and ST Population", January 2005. Rs. 35.
- 153*. Jaya Prakash Pradhan, "Outward Foreign Direct Investment from India: Recent Trends and Patterns", February 2005. Rs. 35.

- 154*. Puttaswamaiah S., "Drinking Water Supply: Environmental Problems, Causes, Impacts and Remedies – Experiences from Karnataka", March 2005. Rs. 35.
- 155*. Keshab Das and Pritee Sharma, "Potable Water for the Rural Poor in Arid Rajasthan: Traditional Water Harvesting as an Option", March 2005. Rs. 30.
156. Jaya Prakash Pradhan and Vinoj Abraham, "Attracting Export-Oriented FDI: Can India Win the Race?", April 2005. Rs. 30.
- 157*. Jaya Prakash Pradhan and Puttaswamaiah S., "Trends and Patterns of Technology Acquisition in Indian Organized Manufacturing: An Inter-industry Exploration", May 2005. Rs. 50.
- 158*. Keshab Das and Ruchi Gupta, "Management by Participation? Village Institutions and Drinking Water Supply in Gujarat", June 2005. Rs. 30. (OS)
- 159*. Keshab Das, "Industrial Clusters in India: Perspectives and Issues for Research", July 2005. Rs. 30. (OS)
160. Jeemol Unni and Uma Rani, "Home-based Work in India: A Disappearing Continuum of Dependence?", August 2005. Rs. 35. (OS)
- 161*. N. Lalitha, "Essential Drugs in Government Healthcare: Emerging Model of Procurement and Supply", September 2005. Rs. 35. (OS)
- 162*. Puttaswamaiah S., Ian Manns and Amita Shah, "Promoting Sustainable Agriculture: Experiences from India and Canada", October 2005. Rs. 35. (OS)
163. Amalendu Jyotishi, "Transcending Sustainability beyond CBA: Conceptual Insights from Empirical Study on Shifting Cultivation in Orissa", November 2005. Rs. 30. (OS)
164. Sashi Sivramkrishna and Amalendu Jyotishi, "Monopsonistic Exploitation in Contract Farming: Articulating a Strategy for Grower Cooperation", December 2005. Rs. 30. (OS)
165. Keshab Das, "Infrastructure and Growth in a Regional Context: Indian States since the 1980s", December 2005. Rs. 30. (OS)
166. Leela Visaria, Alka Barua and Ramkrishna Mistry, "Medical Abortion: Some Exploratory Findings from Gujarat", January 2006. Rs. 35.
- 167*. Manoj Alagarajan and P.M. Kulkarni, "Trends in Religious Differentials in Fertility, Kerala, India: An Analysis of Birth Interval", February 2006. Rs. 30. (OS)

- 168*. N. Lalitha and Diana Joseph, "Patents and Biopharmaceuticals in India: Emerging Issues, March 2006. Rs. 35.
169. Sashi Sivramkrishna and Amalendu Jyotishi, "Hobbes, Coase and Baliraja: Equity and Equality in Surface Water Distribution", April 2006. Rs. 30.
170. Amita Shah, "Changing Interface Between Agriculture and Livestock: A Study of Livelihood Options under Dry Land Farming Systems in Gujarat", May 2006. Rs. 35.
- 171*. Keshab Das, "Micro and Small Enterprises during Reforms: Policy and Concerns", July 2006. Rs. 25.
- 172*. Keshab Das, "Electricity and Rural Development Linkage", August 2006. Rs. 30.
173. Keshab Das, "Traditional Water Harvesting for Domestic Use: Potential and Relevance of Village Tanks in Gujarat's Desert Region", November 2006. Rs. 30.
- 174*. Samira Guennif and N. Lalitha, "TRIPS Plus Agreements and Issues in Access to Medicines in Developing Countries", May 2007. Rs. 30.
- 175*. N. Lalitha, "Government Intervention and Prices of Medicines: Lessons from Tamil Nadu", July 2007. Rs. 30.
- 176*. Amita Shah and Jignasu Yagnik, "Estimates of BPL-households in Rural Gujarat: Measurement, Spatial Pattern and Policy Imperatives", August 2007. Rs. 35.
- 177*. P.K. Viswanathan, "Critical Issues Facing China's Rubber Industry in the Era of Economic Integration: An Analysis in Retrospect and Prospect", September 2007. Rs. 35.
178. RudraNarayan Mishra, "Nutritional Deprivation among Indian Pre-school Children: Does Rural-Urban Disparity Matter?", October 2007. Rs. 35.
- 179*. Amita Shah, "Patterns, Processes of Reproduction, and Policy Imperatives for Poverty in Remote Rural Areas: A Case Study of Southern Orissa in India", November 2007. Rs. 40.
- 180*. N. Lalitha and Samira Guennif, "A Status Paper on the Pharmaceutical Industry in France", December 2007. Rs. 30.
- 181*. Keshab Das, "Micro, Small and Medium Enterprises in India: Unfair Fare", January 2008. Rs. 40.

182. Bharat Ramaswami, Carl E Pray and N. Lalitha, "The Limits of Intellectual Property Rights: Lessons from the spread of Illegal Transgenic Cotton Seeds in India", February 2008. Rs. 45.
183. Keshab Das, "Drinking Water and Sanitation in Rural Madhya Pradesh: Recent Initiatives and Issues", April 2008. Rs. 40.
184. N. Lalitha, "Doha Declaration and Compulsory License for Access to Medicines", June 2008. Rs. 40.
- 185*. Keshab Das and Aswini Kumar Mishra, "Ensuring Horizontal Equity: Challenges before the 13th Finance Commission", July 2008. Rs. 35.
- 186*. Jeemol Unni, "Are Gender Differentials in Educational Capabilities Mediated through Institutions of Caste and Religion in India?", September 2008. Rs. 40.
- 187*. Amita Shah and Sajitha O.G., "Poverty and Livelihood among Tribals in Gujarat: Status, Opportunities, and Strategies", October 2008. Rs. 45.

About GIDR

The Gujarat Institute of Development Research (GIDR), established in 1970, is a premier social science research institute recognised and supported by the Indian Council of Social Science Research (ICSSR), New Delhi and the Government of Gujarat.

The major areas of research at the institute include:

- **Natural Resources Development and Management**
- **Poverty, Employment and Human Development**
- **Industry, Trade and Infrastructure**

In Natural Resources Development and Management, the studies relate to agriculture, irrigation, watershed, forestry and common property resources. The research on Poverty, Employment and Human Development focuses on demography, labour, migration, informal sector, nutrition and health, gender relations, drinking water, poverty issues that related to disparities in quality of life, education and social sector, livelihood and social security issues. The focus of research related to Industry, Trade and Infrastructure relates to various dimensions of small enterprises development, industrial clusters, WTO, intellectual property rights, agricultural trade, and rural and urban infrastructure.

Being integral as they are to the above themes, research often focuses on aspects of *Policies, Institutions and Governance*. The institute also undertakes collaborative research and has a network with NGOs, international organisations, governments, and academic institutions.



Gota, Ahmedabad - 380 060. Gujarat, India
Tel: 91-2717-232623/366/368
Fax: 91-2717-242365
Email: gidr@gidr.ac.in
Website: www.gidr.ac.in